Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term efficacy. Found 21 abstracts

no pagination
Stitzenberg KB, Shah PC, Snyder JA, Scott WJ. Disparities in Access to Video-Assisted Thoracic Surgical Lobectomy for Treatment of Early-Stage Lung Cancer. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2012 Oct;22(8):753-7.
Stitzenberg KB, Shah PC, Snyder JA, Scott WJ. Disparities in Access to Video-Assisted Thoracic Surgical Lobectomy for Treatment of Early-Stage Lung Cancer. Journal of Laparoendoscopic & Advanced Surgical Techniques. 2012 Oct;22(8):753-7.   PMCID: Private funding
Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao LC, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. European Urology. 2012 Dec;62(6):1013-9.   PMCID: No NIH
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Weiss RF, Miller MG, Cronin JF, Hensley HH, Joshi ID, Smith MR. Parametric Model of Combination Therapy for Non-Hodgkin Lymphoma. Plos One. 2012 Dec;7(12):e51736.   PMCID: PMC 3522695
Plimack ER, Hudes GR. Selecting Targeted Therapies for Patients With Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):997-1007.   PMCID: not NIH funded
Tsimberidou AM, Lewis N, Reid T, Burris H, Urban P, Tan EY, Anand S, Uehara C, Kurzrock R. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 2011 Dec;68(6):1507-16.   PMCID: not NIH funded
Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, Schmidt-Wolf IG, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Fayad L. Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. 2010 Apr;28(12):2085-93.   PMCID: Not NIH funded
Manne S, Jacobsen PB, Ming ME, Winkel G, Dessureault S, Lessin SR. Tailored Versus Generic Interventions for Skin Cancer Risk Reduction for Family Members of Melanoma Patients. Health Psychology. 2010 Nov;29(6):583-93.   PMCID: PMC3058834
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, Reynolds P. Nicotine patch vs. nicotine lozenge for smoking cessation: An effectiveness trial coordinated by the Community Clinical Oncology Program. Drug and alcohol dependence. 2010 Mar;107(2-3):237-43.   PMCID: PMC2834192
Emmanouilides C, Witzig TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. Leukemia & lymphoma. 2006 Apr;47(4):629-36.
Meropol NJ. Turning point for colorectal cancer clinical trials. JOURNAL OF CLINICAL ONCOLOGY. 2006 Jul;24(21):3322-4.
Russo J, Mailo D, Hu YF, Balogh G, Sheriff F, Russo IH. Breast differentiation and its implication in cancer prevention. Clinical Cancer Research. 2005 Jan 15;11(2):931S-936S.
Miller SM, Buzaglo JS, Simms SL, Green V, Bales C, Mangan CE, Sedlacek TV. Monitoring styles in women at risk for cervical cancer: Implications for the framing of health-relevant messages. Annals of Behavioral Medicine. 1999 Jan;21(1):27-34.
Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB, McDonald A, Selinger K, Wissel P, O'Dwyer PJ, Twelves C. Phase I pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Annals of Oncology. 1999 Mar;10(3):339-44.
Hadley D, Fowble B, Torosian MH. Evidence for selective use of bone scans in early stage breast cancer. Oncology reports. 1998 Jul;5(4):991-3.
Houghton A, Coit D, Bloomer W, Buzaid A, Chu D, Eisenberg B, Guitart J, Johnson T, Miller S, Sener S, Tanabe K, Thompson J, Urist M, Walker M. NCCN Melanoma Practice Guidelines. Oncology-New York. 1998 Jul;12(7A):153-77.
Miller SM, Shoda Y, Hurley K. Applying cognitive social theory to health-protective behavior: Breast self-examination in cancer screening. Psychological Bulletin. 1996 Jan;119(1):70-94.
Yeh KA, Fortunato L, Ridge JA, Hoffman JP, Eisenberg BL, Sigurdson ER. Routine Bone Scanning in Patients with T1 and T2 Breast-Cancer - a Waste of Money. Annals of Surgical Oncology. 1995 Jul;2(4):319-24.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term efficacy

efficacy therapy bevacizumab safety interferon-alpha sunitinib malignant-melanoma lymphoma risk coping style breast cancer attitudes surgery lobectomy antitumor-activity follow-up Oncology cancer thoracotomy information cutaneous melanoma trial scintigraphy person variables cetuximab Toll-like receptor 4 agonist chemical carcinogens mutations excision prevention tamoxifen antibody-targeted chemotherapy temsirolimus immunoglobulin sequences varenicline improves survival family members Pharmacokinetics cmc-544 renal cell hispanic women anti-cd20 monoclonal-antibody transgenic mice dependence papillary young-women apoptosis randomized-trial phase I immunotherapy colorectal-cancer self-medication family history phase-iii trial Omeprazole intentions abstinence ovarian-cancer topotecan prophylactic mastectomy gi147211 breast self-examination oncology-group Sunitinib Non-clear cell renal cell carcinoma-Targeted therapy-Renal cell carcinoma variant histology-Papillary renal cell carcinoma-Chromophobe renal cell carcinoma prevention practices subsequent plus irinotecan follicular metastatic metastases epothilones 1991 ing ms-british journal of clinical pharmacology-v31-p166 Midazolam phase-i base-line bone scan kidney neoplasms protective behavior 4 mm receptor agonists precaution adoption process camptothecin pathology radioimmunotherapy behavior inhibitor potent Carcinoma antisense oligonucleotides complementary transformation melanoma patients 2010 dermott df-v28 epithelial-cells interview women lymph-node dissection adherence birth threat erlotinib chemotherapy oxaliplatin transcript Drug interaction follow-up bone scan genetics lymphadenectomy microtubule-stabilizing agents growth-factor receptor gefitinib medullary sun protection sorafenib cd22-targeted immunoconjugate replacement therapy skeletal metastases Hematology Phase 1 age first relapse Nicotine replacement therapy Smoking cessation-Nicotine dependence-Moderators GG211 xenografts antitumor antibiotics gemtuzumab ozogamicin mammography utilization clear cell renal cell carcinoma calicheamicin camptothecin analogues expression non-clear cell renal cell carcinoma carcinoma individuals Patupilone bone pain ibritumomab tiuxetan Solid tumors belief model Transgenic mouse low-grade disease iii trial intervention topoisomerase I inhibitors protein collecting duct carcinoma HER2 sustained-release bupropion fc-gamma-ri fluorouracil Antibody therapy antibody
Last updated on Wednesday, February 05, 2020